Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1953 1
1954 1
1955 1
1957 1
1960 3
1961 3
1962 8
1963 7
1964 9
1965 7
1966 17
1967 13
1968 12
1969 25
1970 21
1971 19
1972 15
1973 13
1974 13
1975 20
1976 33
1977 26
1978 39
1979 34
1980 29
1981 50
1982 39
1983 49
1984 48
1985 68
1986 63
1987 63
1988 67
1989 77
1990 77
1991 73
1992 69
1993 78
1994 73
1995 88
1996 93
1997 99
1998 95
1999 99
2000 134
2001 126
2002 141
2003 139
2004 130
2005 122
2006 143
2007 141
2008 136
2009 184
2010 198
2011 182
2012 218
2013 200
2014 194
2015 237
2016 268
2017 273
2018 315
2019 294
2020 355
2021 386
2022 398
2023 421
2024 80

Text availability

Article attribute

Article type

Publication date

Search Results

6,489 results

Results by year

Filters applied: . Clear all
Page 1
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, García-Gutiérrez V, Kapoor S, Allepuz A, Quenet S, Bédoucha V, Mauro MJ. Hochhaus A, et al. Among authors: sasaki k. Leukemia. 2023 Mar;37(3):617-626. doi: 10.1038/s41375-023-01829-9. Epub 2023 Jan 30. Leukemia. 2023. PMID: 36717654 Free PMC article. Clinical Trial.
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
Bhatia V, Kamat NV, Pariva TE, Wu LT, Tsao A, Sasaki K, Sun H, Javier G, Nutt S, Coleman I, Hitchcock L, Zhang A, Rudoy D, Gulati R, Patel RA, Roudier MP, True LD, Srivastava S, Morrissey CM, Haffner MC, Nelson PS, Priceman SJ, Ishihara J, Lee JK. Bhatia V, et al. Among authors: sasaki k. Nat Commun. 2023 Apr 11;14(1):2041. doi: 10.1038/s41467-023-37874-2. Nat Commun. 2023. PMID: 37041154 Free PMC article.
Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma.
Chijimatsu R, Kobayashi S, Takeda Y, Kitakaze M, Tatekawa S, Arao Y, Nakayama M, Tachibana N, Saito T, Ennishi D, Tomida S, Sasaki K, Yamada D, Tomimaru Y, Takahashi H, Okuzaki D, Motooka D, Ohshiro T, Taniguchi M, Suzuki Y, Ogawa K, Mori M, Doki Y, Eguchi H, Ishii H. Chijimatsu R, et al. Among authors: sasaki k. iScience. 2022 Jun 22;25(8):104659. doi: 10.1016/j.isci.2022.104659. eCollection 2022 Aug 19. iScience. 2022. PMID: 35847558 Free PMC article.
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Kantarjian H, et al. Among authors: sasaki k. Am J Hematol. 2023 Mar;98(3):493-501. doi: 10.1002/ajh.26816. Epub 2023 Jan 4. Am J Hematol. 2023. PMID: 36600670
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Jabbour E, et al. Among authors: sasaki k. Lancet Haematol. 2023 Jun;10(6):e433-e444. doi: 10.1016/S2352-3026(23)00073-X. Epub 2023 May 12. Lancet Haematol. 2023. PMID: 37187201 Clinical Trial.
Ready-to-Use-Type Lyophilized Lipid Nanoparticle Formulation for the Postencapsulation of Messenger RNA.
Tanaka H, Hagiwara S, Shirane D, Yamakawa T, Sato Y, Matsumoto C, Ishizaki K, Hishinuma M, Chida K, Sasaki K, Yonemochi E, Ueda K, Higashi K, Moribe K, Tadokoro T, Maenaka K, Taneichi S, Nakai Y, Tange K, Sakurai Y, Akita H. Tanaka H, et al. Among authors: sasaki k. ACS Nano. 2023 Feb 14;17(3):2588-2601. doi: 10.1021/acsnano.2c10501. Epub 2023 Jan 31. ACS Nano. 2023. PMID: 36719091
6,489 results